Clinical trials · New York
Obesity clinical trials in New York
We’re tracking 85 recruiting obesity studies with a site in New York — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05770570RecruitingPhase 2
Diet and activity texting support for Mexican American drivers
This Phase 2 study tests a structured program using texts and recordings to help people improve diet and physical activity for weight loss. It focuses on specific Spanish-speaking groups and also includes a separate track for taxi/FHV drivers.
New York, New YorkAges 21 years+ - NCT07595549RecruitingPhase 3
Testing Berobenatide for Weight Loss in Overweight Adults
This study tests a new medicine called berobenatide to help people with overweight or obesity lose weight. The medicine may also help improve related health conditions like high blood pressure, high cholesterol, or type 2 diabetes.
Rochester, New YorkAges 18 years+ - NCT07392190RecruitingPhase 3
Study of eloralintide for people with persistent obesity
This trial tests if adding eloralintide helps people who are still obese or overweight while taking weekly incretin therapy. It aims to support additional weight loss for those who haven't reached their goals.
New York, New YorkAges 18 years+ - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
New York, New YorkAges 18–70 - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
New York, New YorkAges 18–70 - NCT07567001RecruitingPhase 3
Testing NNC0487-0111 for Heart Failure and Obesity
This study tests whether a new medication called NNC0487-0111 can help people with heart failure who also have obesity. Researchers will compare it to a placebo (inactive pill) to see if it improves heart function and overall health.
Albany, New YorkAges 18 years+ - NCT07743463RecruitingPhase 3
Daily pill for weight loss in adults with overweight or obesity
This trial tests an investigational once-daily pill (ASC30) to see if it can help adults with overweight or obesity lose weight. You may be able to join if you have a high body mass index (BMI) and have tried to lose weight before.
New Windsor, New YorkAges 18 years+ - NCT07743450RecruitingPhase 3
Once-daily pill for weight loss in people with type 2 diabetes
This study tests an oral medication, ASC30, to see if it helps people with type 2 diabetes who are overweight or obese lose weight and improve blood sugar control. It is a once-daily pill that may offer a new treatment option.
East Northport, New YorkAges 18 years+ - NCT07351045RecruitingPhase 3
Study of enicepatide for weight loss in obesity or overweight
This study tests a new injectable medication called enicepatide for people with obesity or overweight who have not been able to lose weight through diet and exercise alone. It may help you lose weight and improve health conditions linked to excess weight.
Buffalo, New YorkAges 18 years+ - NCT07654374RecruitingPhase 3
Study of a new pill for weight loss and diabetes
This study tests a new daily pill (aleniglipron) to help adults with excess weight and type 2 diabetes lose weight and improve blood sugar control. It may be a good fit if you have a BMI of 27 or higher and your diabetes is managed with A1c between 6.5% and 10%.
Albany, New YorkAges 18–79 - NCT07654361RecruitingPhase 3
A new pill for weight loss in obesity and overweight
This study tests an investigational pill called aleniglipron to see if it helps people with obesity or overweight who also have a weight-related health problem (like high blood pressure) lose weight safely. It is a Phase 3 trial, meaning it is in the final stages before seeking approval.
Albany, New YorkAges 18–79 - NCT06439277RecruitingPhase 3
Tirzepatide for teens with obesity and related health problems
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
Buffalo, New YorkAges 12–17 - NCT06899178RecruitingPhase 2
Atomoxetine for genetic obesity due to MC4R changes
This trial tests a medicine called atomoxetine (Strattera) to help people with a specific genetic form of obesity lose weight. It may be an option if you have a change in the MC4R gene and have not used certain other medications recently.
New York, New YorkAges 6 years+ - NCT07353931RecruitingPhase 3
Study of eloralintide for knee osteoarthritis pain in people with overweight or obesity
This trial tests an investigational drug called eloralintide to see if it can reduce knee pain in people with osteoarthritis who also have overweight or obesity. You may be able to join if you have knee osteoarthritis, a BMI of 27 or higher, and have tried to lose weight with diet before.
Brooklyn, New YorkAges 18 years+ - NCT07369011RecruitingPhase 3
Study of eloralintide for sleep apnea with obesity
This study tests an investigational medication called eloralintide to see if it can improve sleep apnea in people who are overweight or have obesity. You will receive either the study drug or a placebo (inactive shot), and your sleep and weight will be monitored over time.
Buffalo, New YorkAges 18 years+ - NCT07254065Recruiting
Preventing obesity early with telehealth support
This study tests a telehealth program to help prevent obesity in pregnant women. It offers support and education through video calls to promote healthy habits.
New Hyde Park, New YorkAges 18 years+ - NCT03514602Recruiting
Help quitting smoking to prevent childhood obesity
This study supports pregnant people who smoke to quit or cut down, using behavior-based coaching. It also measures how changes in smoking may help lower a child’s risk of developing obesity.
Buffalo, New YorkAges 18–39 - NCT07037433RecruitingPhase 3
Heart protection study for people with heart disease and overweight
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Binghamton, New YorkAges 45–99 - NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
New York, New YorkAges 18–99 - NCT07284979RecruitingPhase 3
Weekly injection for obesity without diabetes
This trial tests a new once-weekly injection called Ribupatide for weight loss in people with obesity who do not have diabetes. It compares the study drug to an existing medication (semaglutide) and a placebo to see how well it works and if it's safe.
Albany, New YorkAges 18 years+ - NCT07284875RecruitingPhase 3
Ribupatide for weight loss in adults without diabetes
This trial tests a new medication, Ribupatide, to see if it helps people with obesity or overweight who also have weight-related health problems. You cannot have diabetes to join.
Rochester, New YorkAges 18 years+ - NCT06672549RecruitingPhase 3
Weight loss medication study for children with obesity
This trial tests a medication for children and teens with obesity or overweight who have not been able to lose enough weight with diet and exercise alone. It aims to see if a new treatment can help them safely lose weight and improve related health problems.
Buffalo, New YorkAges 6–17 - NCT07321886RecruitingPhase 3
Study of eloralintide for people with obesity or overweight
This trial tests if an investigational drug called eloralintide can help people with obesity or overweight lose weight. It is for people who do not have type 2 diabetes and who have tried but struggled to lose weight on their own.
Rochester, New YorkAges 18 years+ - NCT07284901RecruitingPhase 3
Weekly injection for diabetes and weight loss
This study tests an experimental once-weekly injection called ribupatide for people with type 2 diabetes and overweight. It aims to help them lose weight and better control their blood sugar.
Albany, New YorkAges 18 years+
Obesity trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting obesity studies listed above.
- Rochester Clinical Research, LLC · 5 studies
- Rochester Clinical Research · 3 studies
- ACCOMPLISH Research Site · 2 studies
- AURORA Clinical Sites · 2 studies
- Care Access - Yonkers · 2 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Kailera Clinical Site · 2 studies
- Mount Sinai Hospital · 2 studies
What taking part in a obesity study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Obesity trials in other states
Common questions
- Are there obesity clinical trials in New York?
- Yes. We're currently tracking 85 recruiting obesity studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a obesity study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a obesity trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New obesity studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.